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Time for a randomised clinical trial evaluating breast conserving surgery compared to 
mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? 
Nijenhuis et al. (2015) are to be commended for reviewing the role of breast-conserving surgery (BCS) in the treatment 
of Multi- focal Breast Cancers (MFBC) [1]. Currently, evidence-based guide- lines on recommended surgical treatments 
in MFBC are based on limited evidence. A systematic review [2] critically evaluating the published literature has led us 
to conclude the following: 1) Studies of MFBC would benefit from standardized imaging, ideally with MRI providing 
detailed and accurate anatomic extent; 2) Modern trials would ideally evaluate neoadjuvant therapy, where therapeutic 
response can be evaluated; 3) Tumour subtype (immunohistochemical markers) of  each  cancer  should  be  used in a 
minimized randomization design; 4) There is poor clinical evidence for the feasibility of dual tumour bed radiotherapy 
(RT) boosting and its impact on  outcomes;  5)  Meta-analyses  on  RT for unifocal cancers underline the significance of 
10-year first recurrence and not breast cancer death; 6) Effect-sizes for 5-year local recurrence requires intergroup 
comparisons of surgery types (BCS versus mastectomy) far in excess of reported studies, where multicentric cancers are 
included and MFBC are clinically diagnosed; 7) Lack of convincing outcomes data on 5-year local recurrence after 
BCS is motivating a large international collaborative supported by respective  international  and  national  associations 
of breast surgery. 
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